The Office of Biomedical Advanced Research and Development Authority (BARDA) seeks to advance investigational BDBV vaccine candidates using the VSV vaccine platform, including manufacturing process development and production of up to 10,000 doses of cGMP Phase 1 clinical trial material. The effort also includes a Phase 1 safety and immunogenicity trial, with options for production of up to 100,000 doses of cGMP clinical trial material. The goal is to produce material and meet regulatory requirements for use in a clinical trial for the ongoing 2026 BDBV outbreak, and to identify successful candidates for further development. No budget amount is specified. The location for performance of services is not mentioned.

BARDA seeks to advance investigational BDBV vaccine candidates using the VSV platform, including manufacturing process development and production of up to 10,000 doses of Phase 1 clinical trial material. The effort also includes a Phase 1 safety and immunogenicity trial, with options for up to 100,000 additional doses. The goal is to produce cGMP material and meet regulatory requirements for a clinical trial addressing the ongoing 2026 BDBV outbreak. No budget amount is specified. The location for performance of services is not mentioned.